Nasdaq:US$16.32 (+0.02) | HKEX:HK$26.50 (+0.65) | AIM:£2.45 (-0.03)
搜索
新聞檔案

通過選擇所需的新聞類型，可以獲得最新的公告或演示文稿。

請使用 「新聞主題」進一步挑選公告類別。

所有公告的全文可以PDF文件的形式下載。 為方便起見，某些公告的部分或全部文字內容以網頁的方式呈現。 如存有任何不一致之處，請以PDF版本為準。

新聞類型
公告及新聞稿
演示文稿
新聞主題
其他業務
監管通知
腫瘤學 / 免疫學
集團
1
2
找到相關結果： 88
演示文稿, 科學出版物 | 2017-09-27

CSCO 2017: FRESCO In-Depth Analysis
In-depth Analysis of the FRESCO Study: a Randomized, Double-blind, Phase III Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients with 3+ Line Advanced Colorectal Cancer Shukui QIN*, Jin LI*, Yuxian BAI, Yanhong DENG, Lei YANG, Zhen
閱讀更多
演示文稿, 科學出版物 | 2017-09-27

CSCO 2017: Theliatinib Preclinical Study in Esophageal Cancer
Is EGFR a “feasible” target for advanced esophageal cancer treatment? Rongxin Ren, Shiming Fan, Linfang Wang,Min Cheng, Dongxia Shi,  Wei Zhang,Renxiang Tang, Ying Yu, Longxian Jiao, Jun Ni, Haibin Yang, Huaqing Cai,Feng Zhou, Weihan Zhang, Wei
閱讀更多
演示文稿, 科學出版物 | 2017-06-23

Journal of Clinical Oncology: Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced PRCC
Toni K. Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, Eric Jonasch, Daniel Y.C. Heng, Thomas Powles, Melanie M. Frigault, Edwin A. Clark, Amir A. Handzel, Humphrey Gardner, Shethah Morgan, Laurence Albiges, and Sumanta Kumar Pal Abstract Pur
閱讀更多
演示文稿, 科學出版物 | 2017-06-05

ASCO 2017: Fruquintinib Phase III in Metastatic Colorectal Cancer (FRESCO)
A randomized, double-blind, placebo-controlled, multi-centered phase III trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO) Venue: American Society of Clinical Oncol
閱讀更多
演示文稿, 科學出版物 | 2017-06-05

ASCO 2017: Sulfatinib Phase II in Medullary and Differentiated Thyroid Cancer
A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) Venue: American Society of Clinical Oncology Annual Meeti
閱讀更多
演示文稿, 科學出版物 | 2017-04-04

AACR 2017: Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF-1R kinases
Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF-1R kinases Authors: Jinghong Zhou, Jun Ni, Min Cheng, Na Yang, Junqing Liang, Liang Ge, Wei Zhang, Jianxing Tang, Qiaoling Sun, Fu Li, Jia Hu,
閱讀更多
演示文稿, 科學出版物 | 2017-04-03

AACR 2017: Fruquintinib combinations with targeted therapies or immune checkpoint inhibitors in preclinical tumor models
Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models Authors: Yongxin Ren, Qiaoling Sun, Jingwen Long, Shiming Fan, Renxiang Tang,
閱讀更多
演示文稿, 科學出版物 | 2017-03-09

ENETS 2017: Sulfatinib Phase Ib/II in Advanced Neuroendocrine Tumors
An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967) Authors: J.M. Xu, J. Li, C.M. Bai, N. Xu, Z.W. Zhou, Z.P. Li, C.C. Zhou, W. Wang, J. Li, C. Qi, Y. Hua, W.G. Su Summary: The current Phase
閱讀更多
演示文稿, 科學出版物 | 2017-01-20

ASCO GI 2017: Fruquintinib in Combination with Paclitaxel in 2L Gastric Cancer
A Phase I/II Trial of Fruquintinib in Combination with Paclitaxel for Second-line Treatment in Patients with Advanced Gastric Cancer Ruihua Xu, Dongsheng Zhang, Lin Shen, Jin Li, Jing Huang, Yang Zhang, Jifang Gong, Weijian Guo, Songhua Fan, Ke Li,
閱讀更多
演示文稿, 科學出版物 | 2017-01-19

Journal of Hematology & Oncology: fruquintinib Phase Ib & Phase II in colorectal cancer
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study   Authors: Rui-Hua Xu, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin She
閱讀更多
演示文稿, 科學出版物 | 2016-12-06

WCLC 2016: Fruquintinib Phase II Study in Advanced NSCLC
A Randomized, Multi-Center, Double-Blind Phase II Study of Fruquintinib in Patients with Advanced Non-Small Cell Lung Cancer  (NCT02590965) Shun Lu1, Jianhua Chang2, XiaoQing Liu3, Jianhua Shi4, You Lu5, Wei Li6, Jinji Yang7, Jianying Zhou8, Jie Wa
閱讀更多
演示文稿, 科學出版物 | 2016-12-06

ASH 2016: Syk Inhibitor HMPL-523 Anti-tumor Activity in vitro and in vivo
HMPL-523, a Novel SYK Inhibitor, Showed Anti-tumor Activities in Vitro and in Vivo Na Yang, Wei Deng, Qiaoling Sun, Junqing Liang, Linfang Wang, Shiming Fan, Renxiang Tang, Ying Yu, Junen Sun, Feng Zhou, Guangxiu Dai, Yongxin Ren, Weiguo Qing and We
閱讀更多
演示文稿, 科學出版物 | 2016-12-05

WCLC 2016: Epitinib in EGFRm+ NSCLC Patients with Brain Metastasis
A Phase Ib study of Epitinib to evaluate efficacy and safety in EGFR mutation positive (EGFRm+) NSCLC patients with brain metastasis Qing Zhou1, Bin Gan1, Qunying Hong2, Mengzhao Wang3, XiaoQing Liu4, Liwei Yuan5, Ye Hua5, Hongcan Ren5, Weiguo Su5,
閱讀更多
演示文稿, 科學出版物 | 2016-11-14

ACR 2016: Phase I Dose Escalating Study of HMPL-523 in Australian Male Healthy Subjects
A Phase I, Randomized, Double Blind, Placebo-Controlled, Dose Escalating Study of the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of HMPL-523 in Australian Male Healthy Subjects   Background: S
閱讀更多
演示文稿, 科學出版物 | 2016-06-03

ASCO 2016: Safety profile and preliminary clinical efficacy of epitinib in EGFRm+ NSCLC
The safety profile of a selective EGFR TKI epitinib (HMPL-813) in patients with advanced solid tumors and preliminary clinical efficacy in EGFRm+ NSCLC patients with brain metastasis Authors: Qing Zhou, Bin Gan, Liwei Yuan, Ye Hua, Yi-Long Wu Ba
閱讀更多
演示文稿, 科學出版物 | 2016-06-03

ASCO 2016: Preliminary results of a phase Ib trial of savolitinib combined with gefitinib in EGFR-mutant lung cancer
Authors: Jin-Ji Yang, Liu Yang, Andrew Farnsworth, Amir Handzel, Tanya Coleman, Shethah Morgan, Yi-Long Wu Background: Savolitinib (AZD6094, volitinib, HMPL-504) is a potent & selective small molecule MET inhibitor. In preclinical models the c
閱讀更多
演示文稿, 科學出版物 | 2016-04-16

AACR 2016: Activity of Savolitinib against MET Ex14 mutations and resistance to METi through decoupling from MYC expression
Abstract (please download the poster for full details) Authors: Evan Barry, Ryan Henry, Alexandra Borodovsky, Elizabeth Maloney, Brendon Ladd, Melanie Frigault, Michael Zinda, Edwin Clark, Alwin Schuller and Celina D’Cruz Alterations in the
閱讀更多
演示文稿, 科學出版物 | 2015-11-07

EORTC 2015: Synergistic effect of c-Met inhibitor Savolitinib in combination with a VEGFR inhibitor Fruquintinib in clear cell renal cell carcinoma xenograft models
Abstract (please download the poster for full details): Authors: Yongxin Ren, Shiming Fan, Yunxin Chen, Renxiang Tang, Wei Zhang, Jianxing Tang, Linfang Wang, Dongxia Shi, Hongbo Chen, Min Cheng, Weiguo Qing, Weiguo Su Renal cell carcinoma (RCC
閱讀更多
演示文稿, 科學出版物 | 2015-11-06

EORTC 2015: First-in-human phase I study of selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors
Abstract (download poster for full details): Authors: Jian-Ming Xu, Lin Shen, Yan Wang, Yu-ling Chen, Ru Jia, Jian Wang, Ke Li, Yang Sai, Jing Li, Chuan Qi, Hua Ye, Su Weiguo Background: Sulfatinib is a highly selective oral small molecule inhi
閱讀更多
演示文稿, 科學出版物 | 2015-09-27

ESMO 2015: Phase II trial of fruquintinib in metastatic colorectal cancer
演示文稿, 科學出版物 | 2015-05-01

ASCO 2015: Preliminary results of TATTON, a multi-arm Phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 (savolitinib) or selumetinib in EGFR-mutant lung cancer
Please see http://meetinglibrary.asco.org/content/109556 The associated abstract is available at http://meetinglibrary.asco.org/content/148945-156. Meeting: 2015 ASCO Annual Meeting Session: Developmental Therapeutics – Clinical Pharmacol
閱讀更多
演示文稿, 科學出版物 | 2014-12-23

Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1,2,3 tyrosine kinases for cancer therapy (Cancer Biology & Therapy 2014)
演示文稿, 科學出版物 | 2014-10-14

ACR/ARHP 2014: HM-0523 (HMPL-523), a novel Syk inhibitor, blocks glomerulonephritis and extends life spans in lupus prone MRL/lpr mice
閱讀更多
View Poster (JPG)
演示文稿, 科學出版物 | 2014-06-03

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer
演示文稿, 科學出版物 | 2014-06-03

ASCO 2014: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors
演示文稿, 科學出版物 | 2014-06-03

ASCO 2014: First-in-Human Phase I study of a selective c-Met inhibitor AZD6094 (savolitinib) in patients with advanced solid tumors
演示文稿, 科學出版物 | 2013-10-15

ACR 2013: HMPL-523, a novel Syk inhibitor, significantly ameliorates the severity of arthritis in rodents
演示文稿, 科學出版物 | 2013-04-06

AACR 2013: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor -1, -2, and -3 tyrosine kinases in patients with advanced solid tumors
演示文稿, 科學出版物 | 2013-04-06

AACR 2013: Preclinical disposition and pharmacokinetics of savolitinib, a novel selective cMet inhibitor
演示文稿, 科學出版物 | 2013-04-06

AACR 2013: Synergistic effect of c-Met inhibitor savolitinib in combination with EGFR inhibitor Gefitinib on EGFR-TKI resistant NSCLC model HCC827C4R harboring acquired Met gene amplification
演示文稿, 科學出版物 | 2013-04-06

AACR 2013: HMPL-504 (savolitinib), a novel, selective and potent cMET inhibitor, is efficacious in primary tumor models of cMET-driven gastric cancer
演示文稿, 科學出版物 | 2012-12-21

HMPL-004 (Andrographis paniculata extract) Prevents Development of Murine Colitis by Inhibiting T-cell Proliferation and TH1/TH17 Responses (Inflammatory Bowel Diseases 2013)
演示文稿, 科學出版物 | 2012-10-14

ISSX 2012: Pharmacokinetic/Pharmacodynamic Modeling of Epitinib to Evaluate the Anti-cancer Effect on A431 Tumor Xenograft in Nude Mice
演示文稿, 科學出版物 | 2012-10-09

Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis (American Journal of Gastroenterology 2013)
演示文稿, 科學出版物 | 2012-06-01

ASCO 2012: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases in patients with advanced solid tumors
演示文稿, 科學出版物 | 2011-04-06

AACR 2011: Savolitinib (HMPL-504) against subcutaneous xenograft and orthotopic brain tumor models
演示文稿, 科學出版物 | 2010-11-30

Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis – a double-blind comparison with sustained release mesalazine (Alimentary Pharmacology and Therapeutics 2011)
演示文稿, 科學出版物 | 2010-10-16

ISSX 2011: Preclinical assessment of the absorption, distribution, metabolism and excretion of HMPL-013 (fruquintinib), a novel potent and specific VEGFR inhibitor
1
2